Skip to main content

Search

Reset all filters
531 Result(s)
Sort by

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors

Click here to read more about how the use of JARDIANCE reduced the risk of kidney disease progression in adults with established CVD and T2D.
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway

Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
Full data announced in phase III EMPA-KIDNEY trial

Full data announced in phase III EMPA-KIDNEY trial

The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)
Growing with us

Growing with us

We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Our evolved employer value proposition

Our evolved employer value proposition

Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Dan’s Unique Story

Dan’s Unique Story

Each cancer journey is unique. In 2018 Dan was diagnosed with a rare form of sarcoma called dedifferentiated liposarcoma. Learn more about Dan’s unique approach to life with DDLPS.
Sarcoma: An expert’s perspective

Sarcoma: An expert’s perspective

Gary Schwartz, MD, Director of the Case Comprehensive Cancer Center, Cleveland, Ohio, shares his expert perspectives on sarcoma, the importance of early detection, and his hopes for the sarcoma treatment landscape.
Fostering Science | Boehringer Ingelheim US

Fostering Science | Boehringer Ingelheim US

Find out how creating breakthrough medicines to change patients’ lives starts with a commitment to identify the challenges of the future & emerging science.